Contents
What is Mounjaro?
Mounjaro is a brand-name prescription medication manufactured by Eli Lilly. Its active ingredient is tirzepatide, a dual GIP and GLP-1 receptor agonist — the first of its kind. It is FDA-approved for improving blood sugar control in adults with type 2 diabetes.
Mounjaro is the same molecule as Zepbound — which carries FDA approval for chronic weight management and sleep apnea. The only difference between Mounjaro and Zepbound is the FDA indication, not the drug itself.
The Dual Mechanism — Why Mounjaro Works Better
Unlike semaglutide (Ozempic/Wegovy) which activates only GLP-1 receptors, tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This dual action produces synergistically greater metabolic effects:
- GLP-1 receptor activation: Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite via brain signaling
- GIP receptor activation: Enhances insulin secretion through a complementary pathway, directly affects fat cell metabolism, and — critically — appears to counteract the nausea caused by GLP-1 alone
- The combined effect produces greater weight loss and better glycemic control than either mechanism alone
- The GIP component is the likely explanation for why tirzepatide causes less nausea despite producing more weight loss
💡 Tirzepatide is often called a "twincretin" because it activates two incretin hormone receptors. This dual mechanism is why it outperforms all previous GLP-1-only medications in head-to-head comparisons.
Mounjaro Dosing Schedule
Dose Escalation — Up to 20 Weeks to Maximum
⚠️ You do not need to reach 15mg. Many patients achieve excellent blood sugar control and weight loss at 5–10mg and stay there permanently. Escalate based on your response and tolerability.
Clinical Trial Results
| Trial | Dose | Duration | A1C Reduction | Weight Loss |
|---|---|---|---|---|
| SURPASS-1 (T2D) | 15mg | 40 wks | 2.3% | ~9.5kg |
| SURPASS-2 vs Ozempic (T2D) | 15mg | 40 wks | 2.3% vs 1.86% | 13.1kg vs 7.6kg |
| SURMOUNT-1 (no T2D) | 5mg | 72 wks | N/A | 15.0% |
| SURMOUNT-1 (no T2D) | 10mg | 72 wks | N/A | 19.5% |
| SURMOUNT-1 (no T2D) | 15mg | 72 wks | N/A | 20.9% |
| SURMOUNT-5 vs Wegovy | Max | 72 wks | N/A | 20.2% vs 13.7% |
💡 In SURPASS-2, tirzepatide at 15mg reduced A1C by 2.3% compared to 1.86% for semaglutide 1mg — and produced 71% more weight loss (13.1kg vs 7.6kg). This head-to-head trial was a major factor in tirzepatide becoming the preferred GLP-1 for diabetes by many endocrinologists.
Side Effects
Tirzepatide has a significantly better GI tolerability profile than semaglutide despite producing more weight loss.
| Side Effect | Mounjaro Rate | Wegovy Rate (comparison) |
|---|---|---|
| Nausea | ~15% | ~44% |
| Diarrhea | ~17% | ~30% |
| Vomiting | ~6% | ~24% |
| Constipation | ~11% | ~24% |
🚨 Contraindications: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Do not use during pregnancy.
Cost & Insurance
- List price: ~$1,023/month (autoinjector pen)
- With commercial insurance (diabetes): As low as $25/month with Eli Lilly savings card
- Self-pay vials via LillyDirect (as Zepbound): $349–$549/month
- Lilly patient assistance program: Free for eligible uninsured low-income patients
💡 If you don't have diabetes and need to self-pay, Zepbound single-dose vials via LillyDirect at $349–$549/month is the same medication at significantly lower cost. See the Cost & Insurance Guide.
Mounjaro vs Ozempic/Wegovy
| Feature | Mounjaro (tirzepatide) | Ozempic/Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 | GLP-1 only |
| Weight loss (max dose) | ~20.9% | ~14.9% (Wegovy) |
| A1C reduction | ~2.3% | ~1.9% (Ozempic 2mg) |
| Nausea rate | ~15% | ~44% (Wegovy) |
| Head-to-head result | 47% more weight loss | (SURMOUNT-5) |
Mounjaro vs Zepbound
Mounjaro and Zepbound are identical medications — same active ingredient (tirzepatide), same doses, same efficacy, same side effects. The only difference:
- Mounjaro — FDA-approved for type 2 diabetes. Use this if your insurance covers diabetes medications.
- Zepbound — FDA-approved for weight management and sleep apnea. Use this if your insurance covers obesity medications, or if you want the self-pay vial option through LillyDirect.
💡 Your prescriber will choose the brand name based on your diagnosis and insurance. You'll get the same tirzepatide molecule either way.